[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE354957T1 - Durch trans-spaltung erhaltene therapeutische molekule - Google Patents

Durch trans-spaltung erhaltene therapeutische molekule

Info

Publication number
ATE354957T1
ATE354957T1 AT96944760T AT96944760T ATE354957T1 AT E354957 T1 ATE354957 T1 AT E354957T1 AT 96944760 T AT96944760 T AT 96944760T AT 96944760 T AT96944760 T AT 96944760T AT E354957 T1 ATE354957 T1 AT E354957T1
Authority
AT
Austria
Prior art keywords
therapeutic
trans
molecules
therapeutic molecules
cells
Prior art date
Application number
AT96944760T
Other languages
English (en)
Inventor
Lloyd G Mitchell
Original Assignee
Intronn Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21733254&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE354957(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intronn Inc filed Critical Intronn Inc
Application granted granted Critical
Publication of ATE354957T1 publication Critical patent/ATE354957T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C12N2840/445—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor for trans-splicing, e.g. polypyrimidine tract, branch point splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96944760T 1995-12-15 1996-12-13 Durch trans-spaltung erhaltene therapeutische molekule ATE354957T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US871795P 1995-12-15 1995-12-15

Publications (1)

Publication Number Publication Date
ATE354957T1 true ATE354957T1 (de) 2006-03-15

Family

ID=21733254

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96944760T ATE354957T1 (de) 1995-12-15 1996-12-13 Durch trans-spaltung erhaltene therapeutische molekule

Country Status (9)

Country Link
US (1) US6013487A (de)
EP (1) EP0883344B2 (de)
JP (2) JP4321877B2 (de)
AT (1) ATE354957T1 (de)
AU (1) AU730305B2 (de)
CA (1) CA2240494C (de)
DE (1) DE69636937T3 (de)
ES (1) ES2279531T3 (de)
WO (1) WO1997022250A1 (de)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6280978B1 (en) * 1995-12-15 2001-08-28 Intronn Holdings, Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20060088938A1 (en) * 1995-12-15 2006-04-27 Mitchell Lloyd G Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
US20020115207A1 (en) * 1995-12-15 2002-08-22 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20030027250A1 (en) * 1995-12-15 2003-02-06 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20020193580A1 (en) * 1995-12-15 2002-12-19 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20030077754A1 (en) * 1995-12-15 2003-04-24 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20030148937A1 (en) * 1995-12-15 2003-08-07 Mansfield S. Gary Methods and compositions for use in spliceosome mediated RNA trans-splicing
EP1849872A1 (de) * 1998-05-20 2007-10-31 University Of Iowa Research Foundation Adenoassoziierte Virusvektoren und ihre Verwendung
US6436392B1 (en) * 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
JP2009000120A (ja) * 1998-08-13 2009-01-08 Virxsys Corp スプライソソーム媒介ｒｎａトランス−スプライシングにおける使用のための方法及び組成物
AU6258399A (en) * 1998-09-21 2000-04-10 Trustees Of Boston University Intron-mediated recombinant techniques and reagents
US6365377B1 (en) 1999-03-05 2002-04-02 Maxygen, Inc. Recombination of insertion modified nucleic acids
CA2376400A1 (en) 1999-06-08 2000-12-14 University Of Iowa Research Foundation Compounds and methods to enhance raav transduction
US7122335B1 (en) 1999-06-08 2006-10-17 University Of Iowa Research Foundation Compounds and methods to enhance rAAV transduction
GB2355010A (en) * 1999-10-04 2001-04-11 Jan Joris Brosens Use of cell-specific splicing in gene therapy
US7241447B1 (en) 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
GB2362383B (en) * 2000-05-19 2003-12-31 Devgen Nv Gene expression system
DE10057014B8 (de) * 2000-11-17 2008-04-30 Steven Dooley Verfahren zur Herstellung von zielzellspezifischen Arzneimitteln
US20040126774A1 (en) * 2001-01-08 2004-07-01 Mitchell Lioyd G. Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
EP1358203A4 (de) * 2001-01-08 2006-11-22 Intronn Inc Verfahren und zusammensetzung zur verbindung in spliceosom-vermitteltem rna-trans-splicing
US20040038396A1 (en) * 2002-06-05 2004-02-26 Mitchell Lloyd G. Spliceosome mediated RNA trans-splicing for correction of factor VIII genetic defects
US8241622B2 (en) 2001-07-13 2012-08-14 University Of Iowa Research Foundation Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
US20030143612A1 (en) * 2001-07-18 2003-07-31 Pointilliste, Inc. Collections of binding proteins and tags and uses thereof for nested sorting and high throughput screening
DE10139492B4 (de) * 2001-08-13 2004-06-09 Eul, Joachim, Dr. Verfahren zur Reparatur einer mutierten RNA aus einer gendefekten DNA und zum gezielten Abtöten von Tumorzellen durch RNA-Transspleißen sowie Verfahren zum Nachweis von natürlich-transgespleißter zellulärer RNA
WO2003062402A2 (en) * 2002-01-24 2003-07-31 Pointilliste, Inc. Use of collections of binding sites for sample profiling and other applications
US20030153054A1 (en) * 2002-02-12 2003-08-14 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
JP2006505242A (ja) * 2002-02-12 2006-02-16 イントロン，インコーポレーテッド スプライセオソームにより媒介されるｒｎａトランス−スプライシングにおいて使用するための方法および組成物
JP2005518211A (ja) * 2002-02-25 2005-06-23 イントロン，インコーポレーテッド 遺伝子発現のトランススプライシング媒介型イメージング
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy
US20040214263A1 (en) * 2002-03-20 2004-10-28 Mitchell Lloyd G. Spliceosome mediated RNA trans-splicing
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
US7541150B2 (en) 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US20030204861A1 (en) * 2002-04-30 2003-10-30 Madaiah Puttaraju Transgenic animal model for spliceosome-mediated RNA trans-splicing
WO2003092594A2 (en) * 2002-04-30 2003-11-13 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
US7094399B2 (en) * 2002-05-08 2006-08-22 Intronn, Inc. Use of spliceosome mediated RNA trans-splicing to confer cell selective replication to adenoviruses
EP1549755A4 (de) * 2002-06-05 2006-09-20 Intronn Inc Spleissosom-vermitteltes trans-rna-spleissen in stammzellen
JP2005528911A (ja) * 2002-06-05 2005-09-29 イントロン，インコーポレーテッド スプライセオソーム媒介型ｒｎａトランススプライシング、及びスプライセオソーム媒介型ｒｎａトランススプライシングを利用した第ｖｉｉｉ因子の遺伝的欠陥の修正
US20040018622A1 (en) * 2002-07-17 2004-01-29 Mitchell Lloyd G. Spliceosome mediated RNA trans-splicing for correction of skin disorders
US8609831B2 (en) * 2002-09-16 2013-12-17 University Of Southern California RNA-mediated gene modulation
EP1579004B1 (de) * 2002-10-23 2010-06-16 VIRxSYS Corporation Screening-verfahren zur identifizierung wirksamer prä-trans-spleissmoleküle
AU2003287384A1 (en) * 2002-10-30 2004-06-07 Pointilliste, Inc. Systems for capture and analysis of biological particles and methods using the systems
WO2004071641A2 (en) * 2003-02-10 2004-08-26 Pointilliste, Inc. Self-assembling arrays and uses thereof
CA2520016A1 (en) 2003-03-31 2004-10-21 University Of Iowa Research Foundation Pharmico-gene therapy of epithelial sodium channel associated disorders
US20050095648A1 (en) * 2003-10-30 2005-05-05 Mario Geysen Method for designing linear epitopes and algorithm therefor and polypeptide epitopes
US20060018911A1 (en) * 2004-01-12 2006-01-26 Dana Ault-Riche Design of therapeutics and therapeutics
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
US20060177933A1 (en) * 2004-01-23 2006-08-10 Madaiah Puttaraju Expression of apoA-1 and variants thereof using spliceosome mediated RNA trans-splicing
WO2005070948A1 (en) * 2004-01-23 2005-08-04 Intronn, Inc. Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing
US20060094110A1 (en) * 2004-07-30 2006-05-04 Mcgarrity Gerard J Use of spliceosome mediated RNA trans-splicing for immunotherapy
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules
DE102004047492B4 (de) * 2004-09-23 2006-07-20 Jost-Werke Gmbh & Co. Kg Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
CA2583306A1 (en) * 2004-10-08 2006-08-10 Intronn, Inc. Use of rna trans-splicing for antibody gene transfer and antibody polypeptide production
CA2583254A1 (en) * 2004-10-08 2006-04-20 Intronn, Inc. Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
US7871795B2 (en) * 2004-10-08 2011-01-18 Virxsys Corporation Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
US20090191597A1 (en) * 2006-01-20 2009-07-30 Asklepios Biopharmaceutical, Inc. Enhanced production of infectious parvovirus vectors in insect cells
JP5081462B2 (ja) * 2007-02-02 2012-11-28 富士フイルム株式会社 トランススプライシング法による融合タンパク質作製方法
EP2151248A1 (de) * 2008-07-30 2010-02-10 Johann Bauer Verbesserte Prä-mRNA-Trans-Splicing-Moleküle und deren Verwendungen
US8923125B2 (en) * 2008-10-24 2014-12-30 Qualcomm Incorporated Wireless network resource adaptation
EP2396343B1 (de) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modifizierte virusvektoren sowie verfahren zu ihrer herstellung und verwendung
WO2011042556A1 (en) 2009-10-08 2011-04-14 Association Institut De Myologie Nucleic acid molecules and methods for exchanging exon(s) by transsplicing
CN102770529B (zh) 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
EP2524037B1 (de) 2010-01-12 2018-05-16 The University Of North Carolina At Chapel Hill Restriktive umgekehrte endverstärkungen für virusvektoren
WO2012056441A1 (en) * 2010-10-28 2012-05-03 Nanodoc Ltd. Compositions and methods for specific cleavage of exogenous rna in a cell
CA2826273C (en) 2011-02-10 2021-11-02 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
PL3446714T3 (pl) 2011-06-02 2021-11-22 University Of Louisville Research Foundation, Inc. Nanocząstki sprzężone z cząsteczką skierowaną przeciwko nukleolinie
DK2900686T3 (da) 2012-09-28 2020-08-17 Univ North Carolina Chapel Hill Aav-vektorer targeteret til oligodendrocytter
EP2970966A4 (de) 2013-03-15 2016-10-26 Univ North Carolina Synthetische adenoassoziierte virusinvertierte endwiederholungssequenzen
PT2968605T (pt) 2013-03-15 2022-09-22 Univ North Carolina Chapel Hill Métodos e composições para vetores aav de ligação dupla de glicano
PL3164492T3 (pl) 2014-07-03 2020-04-30 F. Hoffmann-La Roche Ag Układy ekspresji polipeptydu
AU2015349759B2 (en) 2014-11-21 2022-01-06 The University Of North Carolina At Chapel Hill Aav vectors targeted to the central nervous system
AU2016206624B2 (en) 2015-01-14 2020-08-06 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
EP3253786A4 (de) 2015-02-06 2018-10-17 The University of North Carolina at Chapel Hill Optimierte genexpressionskassetten des menschlichen gerinnungsfaktors viii und deren verwendung
US10596247B2 (en) 2015-02-20 2020-03-24 Board Of Regents, The University Of Texas System Methods and compositions for attenuated chlamydia as vaccine and vector
WO2016179394A1 (en) 2015-05-05 2016-11-10 Malik Mohammad Tariq Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
ES2865487T3 (es) 2015-09-28 2021-10-15 Univ North Carolina Chapel Hill Métodos y composiciones para vectores virales que evaden los anticuerpos
CA3005474A1 (en) 2015-11-19 2017-05-26 The Trustees Of The University Of Pennsylvania Compositions and methods for correction of heritable ocular disease
EP3390429A4 (de) 2015-12-14 2019-07-17 The University of North Carolina at Chapel Hill Modifizierte kapsidproteine zur verbesserten abgabe von parvovirus-vektoren
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
CA3198936A1 (en) 2016-03-07 2017-09-14 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
SG11201808538QA (en) * 2016-04-01 2018-10-30 Nat Univ Singapore Trans-splicing rna (tsrna)
EP3449250B1 (de) 2016-04-28 2020-11-04 Indiana University Research & Technology Corporation Verfahren und zusammensetzungen zur auflösung von komponenten einer viruspräparation
US12173305B2 (en) 2016-05-26 2024-12-24 University Of Iowa Research Foundation cis and trans requirements for terminal resolution of human bocavirus 1
EP3484470A4 (de) 2016-07-13 2020-02-26 Technion Research & Development Foundation Limited Inhibitoren von cytoplasmischen histondeacetylase-4-komplexen zur behandlung oder prävention von gefäss- oder herzklappenverkalkung
US11597708B2 (en) 2016-09-16 2023-03-07 Hsf Pharmaceuticals Sa Inhibitors of heat shock factors and uses thereof
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
CN110770346B (zh) 2017-03-15 2024-01-12 北卡罗来纳-查佩尔山大学 多倍体腺相关病毒载体及其制备和使用方法
US11668719B2 (en) 2017-09-20 2023-06-06 The Trustees Of Indiana University Methods for resolving lipoproteins with mass spectrometry
US11232941B2 (en) 2018-01-12 2022-01-25 The Trustees Of Indiana University Electrostatic linear ion trap design for charge detection mass spectrometry
EA202092362A1 (ru) 2018-04-03 2021-01-11 Страйдбайо, Инк. Вирусные векторы для нацеливания на ткани глаза
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
JP2021519581A (ja) 2018-04-03 2021-08-12 ストライドバイオ，インコーポレイテッド 抗体を回避するウイルスベクター
AU2019255708A1 (en) 2018-04-17 2020-11-26 Ascidian Therapeutics, Inc. Trans-splicing molecules
CN112673452B (zh) 2018-06-04 2024-08-23 印地安纳大学理事会 用于在静电线性离子阱中捕获离子的设备和方法
CN112703579B (zh) 2018-06-04 2025-01-28 印地安纳大学理事会 用于高通量电荷检测质谱分析的离子阱阵列
KR102742958B1 (ko) 2018-06-04 2024-12-16 더 트러스티즈 오브 인디애나 유니버시티 실시간 분석 및 신호 최적화를 통한 전하 검출 질량 분광분석법
WO2019236143A1 (en) 2018-06-04 2019-12-12 The Trustees Of Indiana University Apparatus and method for calibrating or resetting a charge detector
WO2019236139A1 (en) 2018-06-04 2019-12-12 The Trustees Of Indiana University Interface for transporting ions from an atmospheric pressure environment to a low pressure environment
JP7428664B2 (ja) 2018-06-12 2024-02-06 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 合成肝臓指向性アデノ随伴ウイルスカプシドおよびその使用
CN112639110A (zh) 2018-06-22 2021-04-09 阿斯克肋匹奥生物制药公司 用于基因递送以在细胞内持续存在的载体
AU2019354965A1 (en) 2018-10-04 2021-05-06 University Of Rochester Improvement of glymphatic delivery by manipulating plasma osmolarity
KR102742962B1 (ko) 2018-11-20 2024-12-16 더 트러스티즈 오브 인디애나 유니버시티 단일 입자 질량 분석을 위한 오비트랩
KR102742959B1 (ko) 2018-12-03 2024-12-16 더 트러스티즈 오브 인디애나 유니버시티 정전 선형 이온 트랩을 이용하여 다수의 이온을 동시에 분석하기 위한 장치 및 방법
JP2022525955A (ja) 2019-03-21 2022-05-20 ストライドバイオ，インコーポレイテッド 組換えアデノ随伴ウイルスベクター
CA3137876A1 (en) 2019-04-23 2020-10-29 The Trustees Of Indiana University Identification of sample subspecies based on particle charge behavior under structural change-inducing sample conditions
JP2022529662A (ja) 2019-04-26 2022-06-23 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 二重グリカン結合ａａｖ２．５ベクターのための方法および組成物
CA3156003A1 (en) 2019-09-25 2021-04-01 The Trustees Of Indiana University APPARATUS AND METHOD FOR PERFORMING CHARGE DETECTION MASS SPECTROMETRY IN PULSE MODE
EP4045525A1 (de) 2019-10-17 2022-08-24 Stridebio, Inc. Adeno-assoziierte virusvektoren zur behandlung der niemann-pick-krankheit vom typ c
AU2021216003A1 (en) 2020-02-03 2022-07-14 The Trustees Of Indiana University Time-domain analysis of signals for charge detection mass spectrometry
KR20230034211A (ko) 2020-05-05 2023-03-09 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 변형된 아데노-관련 바이러스 5 캡시드 및 이의 용도
US20230304038A1 (en) 2020-08-19 2023-09-28 Sarepta Therapeutics, Inc. Adeno-associated virus vectors for treatment of rett syndrome
WO2022093769A1 (en) 2020-10-28 2022-05-05 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
JP2023547992A (ja) 2020-10-28 2023-11-15 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 二重グリカン結合ａａｖ２．５ベクターのための方法および組成物
TW202242124A (zh) 2021-01-14 2022-11-01 美商史崔德生物公司 靶向ｔ細胞之ａａｖ載體
CA3216491A1 (en) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
EP4452336A2 (de) 2021-12-23 2024-10-30 University of Rochester Csf-transportpfad zur abgabe von mitteln an das innenohr
JP2025503508A (ja) 2021-12-23 2025-02-04 ユニバーシティ オブ ロチェスター 内耳への薬剤の送達のための組成物及び方法
TW202342759A (zh) 2022-02-04 2023-11-01 美商史崔德生物公司 重組腺相關病毒載體及其使用方法
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
WO2024068898A1 (en) 2022-09-30 2024-04-04 Centre National De La Recherche Scientifique Therapy by trans-splicing of opa1 pre-messenger rnas for the treatment of diseases associated with opa1 gene mutations
WO2024124019A2 (en) 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ314630A (en) * 1991-01-17 2000-11-24 Harvard College Use of trans-splicing ribozymes for genetic modification and cell ablation in a host cell
NZ241310A (en) * 1991-01-17 1995-03-28 Gen Hospital Corp Trans-splicing ribozymes
US5498531A (en) * 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US5667969A (en) * 1993-11-12 1997-09-16 University Research Corporation Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing

Also Published As

Publication number Publication date
EP0883344A1 (de) 1998-12-16
US6013487A (en) 2000-01-11
JP4321877B2 (ja) 2009-08-26
DE69636937D1 (de) 2007-04-12
CA2240494C (en) 2007-03-13
JP2000515362A (ja) 2000-11-21
EP0883344B1 (de) 2007-02-28
WO1997022250A1 (en) 1997-06-26
DE69636937T3 (de) 2011-01-05
EP0883344A4 (de) 2002-08-07
AU1329997A (en) 1997-07-14
ES2279531T3 (es) 2007-08-16
DE69636937T2 (de) 2007-11-22
EP0883344B2 (de) 2010-06-09
CA2240494A1 (en) 1997-06-26
AU730305B2 (en) 2001-03-01
JP2009131276A (ja) 2009-06-18

Similar Documents

Publication Publication Date Title
DE69636937D1 (de) Durch trans-spaltung erhaltene therapeutische molekule
Herold et al. Incorporation of six additional proteins to complete the assembly map of the 50 S subunit from Escherichia coli ribosomes.
HUP0400231A2 (hu) Rákos megbetegedések kezelésében különösen hasznos, immundecepcióra szolgáló eljárások és gyógyszerkészítmények
Miller et al. Stereoselective excision of thymine glycol from oxidatively damaged DNA
BR9915026A (pt) Móleculas de ácido nucléico codificando uma enzima ramificadora de bactérias do gênero neisseria bem como métodos para a produção de alfa-1,4 glicanos ramificados para alfa-1,6
DE60323340D1 (de) Verfahren zur herstellung interferierender rna-moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
ATE493441T1 (de) Multispezifische deimmunisierte cd3-bindende moleküle
WO2003029403A3 (en) Targeting proteins to cells expressing mannose receptors via expression in insect cells
GB2396616A (en) RNA interference mediated inhibition of gene expression using short interfering nucleic acid (SINA)
DE50015772D1 (de) Sequenz-spezifische DNA-Rekombination in eukaryotischen Zellen
WO2008098569A3 (de) Biologisch wirksame moleküle, insbesondere auf grundlage von pna und sirna, verfahren zu deren zellspezifischen aktivierung sowie applikationskit zur verabreichung
ATE448189T1 (de) Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2
DE60019318D1 (de) Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
WO1998032846A3 (en) Enzymatic nucleic acid treatment of diseases or conditions related to levels of c-fos
WO2005034876A3 (en) Use of cell lines to produce active therapeutic proteins
WO2003093428A3 (en) Gene targeting using replicating dna molecules
WO2003106476A8 (en) INHIBITION OF ENTEROCOCCAL INFECTION AND CYTOLYSIN ACTIVITY INDUCED BY NUCLEIC ACIDS
WO2003076610A3 (fr) Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations
ATE248916T1 (de) Gene, die verzweigte-alpha-ketosäure- dehydrogenasekomplexe von streptomyces avermitius kodieren
WO2004013313A3 (en) Antisense nucleic acids
WO2004020979A3 (en) Methods of assaying for cell cycle modulators using components of the ubiquitin ligation cascade
WO2004038036A3 (en) Methods of assaying for modulators of the inflammatory process using components of the ubiquitin ligation cascade
ATE236250T1 (de) Antisense-sequenzen für die hemmung der expression des adhäsionsmoleküls icam-1
ATE288486T1 (de) Zusammensetzung für die behandlung von erkrankungen, die mit apoptose einhergehen
ATE334209T1 (de) Inaktivierung von genen des mep-wegs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties